Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Physiol Int ; 110(2): 173-190, 2023 Jun 12.
Article in English | MEDLINE | ID: mdl-37216221

ABSTRACT

Background and aims: ADAMTS-4 is a protease enzyme involved in vascular remodeling and atherosclerosis. It was found to be upregulated in macrophages seen in atherosclerotic lesions. This study aimed to investigate the expression and regulation of ADAMTS-4 in oxidized LDL-induced human monocytes/macrophages system. Methods: Peripheral blood mononuclear cells (PBMCs) isolated from human blood, and treated with oxidized LDL (50 µg mL-1) were used as the model system for the study. mRNA and protein expressions were studied by PCR, ELISA, and western blot analysis. ROS production and cell viability were determined by DCFDA staining and MTT assay, respectively. Results: In the presence of oxidized LDL, monocytes get differentiated into macrophages, which were confirmed by the increased expression of macrophage differentiation markers and pro-inflammatory cytokine TNF-α. Oxidized LDL increased the mRNA and protein expression of ADAMTS-4 in monocytes/macrophages. N- Acetyl cysteine, ROS scavenger, downregulate the protein expression of ADAMTS-4. The expression of ADAMTS-4 was decreased significantly in the presence of NF-κB inhibitors. SIRT-1 activity was significantly downregulated in the macrophages and was reversed in the presence of the SIRT-1 agonist, resveratrol. Acetylation of NF-κB and hence the expression of ADAMTS-4 were significantly downregulated in the presence of SIRT-1 activator, resveratrol. Conclusions: Our study suggests that oxidized LDL significantly upregulated the expression of ADAMTS-4 in the monocytes/macrophages through ROS- NF-κB- SIRT-1 pathway.


Subject(s)
ADAMTS4 Protein , Atherosclerosis , NF-kappa B , Humans , Atherosclerosis/metabolism , Leukocytes, Mononuclear , Macrophages/metabolism , Monocytes/metabolism , NF-kappa B/metabolism , Reactive Oxygen Species/metabolism , Resveratrol/metabolism , RNA, Messenger/metabolism , Up-Regulation , ADAMTS4 Protein/metabolism
2.
Sci Rep ; 7(1): 10501, 2017 09 05.
Article in English | MEDLINE | ID: mdl-28874825

ABSTRACT

Mitochondrial ATP synthase catalyzes the coupling of oxidative phosphorylation. Under pathological conditions, ATP synthase hydrolyzes ATP to replenish protons from the matrix into the intermembrane space, sustaining mitochondrial membrane potential. ATPase inhibitory factor 1 (IF1) is a nuclear-encoded, ATP synthase-interacting protein that selectively inhibits the hydrolysis activity of ATP synthase, which may render the protective role of IF1 in ischemic hearts. However, the in vivo cardiac function of IF1 and the potential therapeutic application targeting IF1 remain obscure. In the present study, we uncovered that IF1 is upregulated in mouse hearts with pressure overload-induced hypertrophy and in human hearts with dilated cardiomyopathy. IF1 knockout (KO) mice were protected against cardiac dysfunction and pathological development induced by transverse aortic constriction (TAC) or isoproterenol infusion. The reduced ATP hydrolysis activated AMPK activity in IF1 KO hearts, which together facilitated autophagy. These results suggest that IF1 upregulation in the failing heart may be a maladaptive response. Inhibiting IF1 in the hypertrophied heart not only prevents cell death from excessive mitochondrial depolarization but also activates AMPK signaling and increases autophagy. Therefore, IF1 inhibition may serve as a potential therapeutic target in treating pathological cardiac hypertrophy and heart failure.


Subject(s)
Cardiomegaly/genetics , Cardiomegaly/physiopathology , Gene Knockout Techniques , Proteins/genetics , Venous Pressure , Animals , Apoptosis/genetics , Autophagy , Cardiomegaly/diagnosis , Disease Models, Animal , Echocardiography , Heart Function Tests , MAP Kinase Signaling System , Membrane Potential, Mitochondrial , Mice , Mice, Knockout , Mitochondria/genetics , Mitochondria/metabolism , ATPase Inhibitory Protein
SELECTION OF CITATIONS
SEARCH DETAIL